Histogen and Conatus Pharmaceuticals announced a merger agreement. Under the deal, Histogen will merge with a wholly-owned subsidiary of Conatus in an all-stock transaction. The merged companies will operate under the name Histogen and trade on the Nasdaq Capital Market under a new ticker symbol.
Histogen’s lead product candidate is HST 001 or Hair Stimulating Complex (HSC). It is a minimally invasive treatment to treat male pattern hair loss. It is also developing HST 002, a human-derived collagen and extracellular matrix dermal filler. Another product, HST 003, is an extracellular matrix scaffold to treat articular cartilage defects. The company believes all three candidates will reach “clinical and regulatory inflection points in 2020.”
“This merger is transformative for Histogen as we look to advance our novel regenerative medicine pipeline,” said Richard Pascoe, chairman and chief executive officer of Histogen. “We believe the target product profile of our product candidates combined with their market potential provides an opportunity for Histogen to become a leader in the aesthetics and orthopedic medicine markets.”
Conatus focused on novel therapies for chronic diseases. Its lead in-licensed compound was emricasan, which was being developed in collaboration with Novartis for patients with nonalcoholic steatohepatitis (NASH)-driven chronic liver diseases. It also has an internally developed compound, CTS-2090, which is being developed for patients with chronic diseases involving inflammasome pathways.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Biospace